<DOC>
	<DOCNO>NCT02862132</DOCNO>
	<brief_summary>Vedolizumab ( VDZ ) humanize immunoglobulin G1 monoclonal antibody act α4β7 integrin modulates lymphocyte traffic gut . Results adult GEMINI-1 GEMINI-2 trial demonstrate clinical efficacy induction maintenance remission ulcerative colitis ( UC ) Crohn 's disease ( CD ) , respectively . Recent real life cohort adult support effectiveness VDZ induce maintain remission , CD UC . In pediatrics , limited data use VDZ besides two retrospective case series . Data immunogenicity therapeutic drug monitoring ( TDM ) VDZ conflict adult practically non-existent child . The investigator aim prospectively explore real life short long term outcome VDZ pediatric IBD ( include growth ) develop prediction model treatment success base VDZ trough level clinical laboratory variable .</brief_summary>
	<brief_title>Predicting Response Vedolizumab Pediatric Inflammatory Bowel Diseases</brief_title>
	<detailed_description>This multi-center prospective cohort study investigator aim enroll 120 child age 18 year , diagnose CD , inflammatory bowel disease unclassified ( IBDU ) UC ( approximately 60 UC/IBDU 60 CD group ) commence Vedolizumab reason discretion treat physician . Patients follow 3 year 8 different time point : week 0 , week 2 , week 6 , week 14 , week 30 , week 54 ( 1 year ) , week 108 ( 2 year ) week 162 ( 3 year ) . Blood work collect visit time venous access insertion drug infusion serum stool sample collect visit 0 , 14 , 30 , 54 .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Children age 18 year . 2 . IBD Diagnosis 3 . Initiating Vedolizumab therapy 1 . Starting Vedolizumab prevent post operative recurrence</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>VDZ : Vedolizumab</keyword>
	<keyword>UC : Ulcerative colitis</keyword>
	<keyword>CD : Crohn 's disease</keyword>
	<keyword>TDM : Therapeutic drug monitoring</keyword>
</DOC>